According to filings with the U.S. Securities and Exchange Commission, Jaguar Health, Inc. is raising up to $10,810,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Jaguar Health, Inc.
Since our inception, we have been committed to identifying and maximizing opportunities to develop and commercialize first-in-class, plant-based prescription medicines. We are focused on leveraging our broad intellectual property portfolio, our robust and far-reaching pipeline, and our extensive botanical library to develop breakthrough remedies to serve the unmet medical needs of people around the globe. Jaguar Healths organizational framework is designed to enable our product pipeline to reach the worlds interconnected marketplace, allowing for development and commercialization opportunities worldwide. Jaguar Health is a commercial-stage pharmaceutical company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, and bowel incontinence. Jaguar Health is led by an executive management team comprised of industry-leading experts. Our Board of Directors is composed of top advisors and provides guidance and support. At Jaguar Health, we prioritize our impact on environmental and social issues. Our focus includes sustainability, community benefit sharing, and recognizing and honoring the wisdom and expertise of the Indigenous healers who first discovered the medicinal properties of specific plants.

To learn more about Jaguar Health, Inc., visit https://jaguar.health/
Jaguar Health, Inc. Linkedin Page: https://www.linkedin.com/company/jaguar-health/

Contact:
Lisa Conte, President and Chief Executive Officer
415-371-8300

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.